Recently released draft guidance for implementing Medicare price caps would allow voluntary provider use of 340B codes on claims, while [...] …
Category: Regulatory
North Carolina hospitals that participate in the 340B program routinely overcharged cancer patients, taxpayers and state employees for oncology drugs, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Groups representing hospitals that rely on the 340B program recently urged congressional advisers against recommending reduced Medicare reimbursement to 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal auditors closed audits with corrective action plans (CAPs) for eight more 340B providers, which brought the fiscal year 2023 [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Arkansas state officials today scheduled a public hearing to enforce the state’s 340B contract pharmacy access law against AstraZeneca, according [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Cosette Pharmaceuticals recently announced refunds to 340B covered entities for 38 medications sold over a year and half. The refunds [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
As part of a report on incentivizing use of accountable care organizations (ACOs), Congress’ primary research arm recently recommended excluding [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Attorneys for both covered entities and drug manufacturers say they expect a significant number of filings to the newly re-established [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The state agency tasked with implementing Maine’s state 340B hospital reporting requirement has proposed a rule with additional data and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...] …